Incyte (INCY) Other Non-Current Liabilities (2013 - 2026)
Incyte posted quarterly Other Non-Current Liabilities of $126.6 million for Q1 2026, down 27.91% year-on-year from $175.6 million in Q1 2025, and down 23.41% on a QoQ basis from $165.3 million in Q4 2025.
Incyte (INCY) has 14 years of Other Non-Current Liabilities data on file, last reported at $126.6 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 27.91% year-over-year to $126.6 million; the trailing twelve-month figure through Mar 2026 stood at $126.6 million (down 27.91% YoY), and the FY2025 full-year result was $165.3 million, down 1.36% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $126.6 million, down from $165.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $184.5 million in Q4 2022 and bottomed at $69.5 million in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $164.8 million (2024), against an average of $148.2 million.
- Peak annual rise in Other Non-Current Liabilities reached 175.76% in 2022, while the deepest fall reached 65.27% in 2022.
- A 5-year view of Other Non-Current Liabilities shows it stood at $184.5 million in 2022, then fell by 19.14% to $149.2 million in 2023, then gained by 12.33% to $167.5 million in 2024, then fell by 1.36% to $165.3 million in 2025, then declined by 23.41% to $126.6 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $126.6 million (Q1 2026), $165.3 million (Q4 2025), and $171.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126.59 Mn |
| Dec 31, 2025 | 165.27 Mn |
| Sep 30, 2025 | 171.18 Mn |
| Jun 30, 2025 | 179.91 Mn |
| Mar 31, 2025 | 175.59 Mn |
| Dec 31, 2024 | 167.54 Mn |
| Sep 30, 2024 | 144.68 Mn |
| Jun 30, 2024 | 142.10 Mn |
| Mar 31, 2024 | 164.84 Mn |
| Dec 31, 2023 | 149.15 Mn |
| Sep 30, 2023 | 133.07 Mn |
| Jun 30, 2023 | 179.49 Mn |
| Mar 31, 2023 | 118.41 Mn |
| Dec 31, 2022 | 184.46 Mn |
| Sep 30, 2022 | 171.81 Mn |
| Jun 30, 2022 | 76.06 Mn |
| Mar 31, 2022 | 69.47 Mn |
| Dec 31, 2021 | 70.41 Mn |
| Sep 30, 2021 | 62.31 Mn |
| Jun 30, 2021 | 219.01 Mn |
| Mar 31, 2021 | 54.46 Mn |
| Dec 31, 2020 | 227.60 Mn |
| Sep 30, 2020 | 232.95 Mn |
| Jun 30, 2020 | 236.49 Mn |
| Mar 31, 2020 | 239.86 Mn |
| Dec 31, 2019 | 242.96 Mn |
| Jun 30, 2019 | 250.07 Mn |
| Mar 31, 2019 | 252.76 Mn |
| Dec 31, 2018 | 21.93 Mn |
| Sep 30, 2018 | 256.34 Mn |
| Jun 30, 2018 | 258.50 Mn |
| Mar 31, 2018 | 21.26 Mn |
| Dec 31, 2017 | 260.15 Mn |
| Sep 30, 2017 | 259.67 Mn |
| Jun 30, 2017 | 12.80 Mn |
| Mar 31, 2017 | 12.62 Mn |
| Dec 31, 2016 | 12.69 Mn |
| Sep 30, 2016 | 10.08 Mn |
| Jun 30, 2016 | 276.31 Mn |
| Mar 31, 2016 | 48.23 Mn |
| Dec 31, 2015 | 48.39 Mn |
| Sep 30, 2015 | 50.86 Mn |
| Jun 30, 2015 | 51.86 Mn |
| Mar 31, 2015 | 52.91 Mn |
| Dec 31, 2014 | 54.55 Mn |
| Sep 30, 2014 | 52.38 Mn |
| Jun 30, 2014 | 44.40 Mn |
| Mar 31, 2014 | 34.04 Mn |
| Dec 31, 2013 | 26.80 Mn |
| Sep 30, 2013 | 3.39 Mn |
| Jun 30, 2013 | 3.43 Mn |